Potent anti-seizure effects of D-leucine

Neurobiology of Disease

Volumn 82, Issue , 2015, Pages 46-53

  Hartman, Adam L ^a,b   Santos, Polan ^a   O'Riordan, Kenneth J ^c   Stafstrom, Carl E ^a,c   Marie Hardwick, J ^a,b,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^d NONE   (United States)

Author keywords

Amino acids; Epilepsy; Kainic acid; Preclinical testing

Indexed keywords

DIAZEPAM; LEUCINE; LYSINE; ANTICONVULSIVE AGENT; KAINIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTISEIZURE ACITVITY; ARTICLE; BRAIN REGION; BRAIN SLICE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG MEGADOSE; IN VITRO STUDY; LIGAND BINDING; LONG TERM POTENTIATION; LOW DRUG DOSE; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; PREMEDICATION; PRIORITY JOURNAL; SEIZURE; SINGLE DRUG DOSE; SYNAPTIC TRANSMISSION; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; SEIZURES; TREATMENT OUTCOME;

ANIMALS; ANTICONVULSANTS; KAINIC ACID; LEUCINE; LONG-TERM POTENTIATION; MALE; MICE; SEIZURES; SYNAPTIC TRANSMISSION; TREATMENT OUTCOME;

EID: 84930960524     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2015.05.013     Document Type: Article

References (66)

1. Banks W.A., Kastin A.J. Leucine modulates peptide transport system-1 across the blood-brain barrier at the stereospecific site within the central nervous system. J. Pharm. Pharmacol. 1991, 43:252-254.
2. Bar-Peled L., Sabatini D.M. Regulation of mTORC1 by amino acids. Trends Cell Biol. 2014, 24:400-406.
3. Barton M.E., et al. Pharmacological characterization of the 6Hz psychomotor seizure model of partial epilepsy. Epilepsy Res. 2001, 47:217-227.
4. Bassoli A., et al. The taste of D- and L-amino acids: In vitro binding assays with cloned human bitter (TAS2Rs) and sweet (TAS1R2/TAS1R3) receptors. Food Chem. 2014, 150:27-33.
5. Besnard J., et al. Automated design of ligands to polypharmacological profiles. Nature 2012, 492:215-220.
6. Bixel M.G., Hamprecht B. Generation of ketone bodies from leucine by cultured astroglial cells. J. Neurochem. 1995, 65:2450-2461.
7. Brodie M.J., et al. Patterns of treatment response in newly diagnosed epilepsy. Neurology 2012, 78:1548-1554.
8. Cheng R.S., Pomeranz B. A combined treatment with D-amino acids and electroacupuncture produces a greater analgesia than either treatment alone; naloxone reverses these effects. Pain 1980, 8:231-236.
9. Clifford D.B., et al. Effect of anticonvulsant drugs on kainic acid-induced epileptiform activity. Exp. Neurol. 1982, 76:156-167.
10. Cota D., et al. Hypothalamic mTOR signaling regulates food intake. Science 2006, 312:927-930.
11. Cramer C.L., et al. Kainic acid and 4-aminopyridine seizure models in mice: evaluation of efficacy of anti-epileptic agents and calcium antagonists. Life Sci. 1994, 54:L271-L275.
12. D'Aniello A., et al. Biological role of D-amino acid oxidase and D-aspartate oxidase. Effects of D-amino acids. J. Biol. Chem. 1993, 268:26941-26949.
13. del Cerro S., et al. Benzodiazepines block long-term potentiation in slices of hippocampus and piriform cortex. Neuroscience 1992, 49:1-6.
14. Dufour F., et al. Modulation of pentylenetetrazol-induced seizure activity by branched-chain amino acids and alpha-ketoisocaproate. Brain Res. 1999, 815:400-404.
15. Ekborg-Ott K.H., Armstrong D.W. Evaluation of the concentration and enantiomeric purity of selected free amino acids in fermented malt beverages (beers). Chirality 1996, 8:49-57.
16. Ercal N., et al. In vitro study of the metabolic effects of D-amino acids. Chirality 1996, 8:24-29.
17. Fox H.L., et al. Amino acid effects on translational repressor 4E-BP1 are mediated primarily by L-leucine in isolated adipocytes. Am. J. Physiol. 1998, 275:C1232-C1238.
18. Freinkel N., et al. Insulin release and phosphate ion efflux from rat pancreatic islets induced by L-leucine and its nonmetabolizable analogue, 2-aminobicyclo[2.2.1]heptane-2-carboxylic acid. Proc. Natl. Acad. Sci. U. S. A. 1976, 73:3403-3407.
19. Fritsch B., et al. Treatment of early and late kainic acid-induced status epilepticus with the noncompetitive AMPA receptor antagonist GYKI 52466. Epilepsia 2010, 51:108-117.
20. Gerstein H., et al. Rescue of synaptic plasticity and spatial learning deficits in the hippocampus of Homer1 knockout mice by recombinant Adeno-associated viral gene delivery of Homer1c. Neurobiol. Learn. Mem. 2012, 97:17-29.
21. Glaser V., et al. The intra-hippocampal leucine administration impairs memory consolidation and LTP generation in rats. Cell. Mol. Neurobiol. 2010, 30:1067-1075.
22. Hamase K., et al. Regional distribution and postnatal changes of D-amino acids in rat brain. Biochim. Biophys. Acta 1997, 1334:214-222.
23. Hamase K., et al. Determination of free D-proline and D-leucine in the brains of mutant mice lacking D-amino acid oxidase activity. Anal. Biochem. 2001, 298:253-258.
24. Hartman A.L., Stafstrom C.E. Harnessing the power of metabolism for seizure prevention: focus on dietary treatments. Epilepsy Behav. 2013, 26:266-272.
25. Hartman A.L., Vining E.P. Clinical aspects of the ketogenic diet. Epilepsia 2007, 48:31-42.
26. Hartman A.L., et al. The neuropharmacology of the ketogenic diet. Pediatr. Neurol. 2007, 36:281-292.
27. Hartman A.L., et al. Efficacy of the ketogenic diet in the 6-Hz seizure test. Epilepsia 2008, 49:334-339.
28. Hartman A.L., et al. Seizure tests distinguish intermittent fasting from the ketogenic diet. Epilepsia 2010, 51:1395-1402.
29. Hartman A.L., et al. The mTOR inhibitor rapamycin has limited acute anticonvulsant effects in mice. PloS One 2012, 7.
30. Hauser W.A., et al. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia 1993, 34:453-468.
31. Kaminski R.M., et al. Topiramate selectively protects against seizures induced by ATPA, a GluR5 kainate receptor agonist. Neuropharmacology 2004, 46:1097-1104.
32. Kobau R., et al. Epilepsy surveillance among adults-19 States, Behavioral Risk Factor Surveillance System, 2005. MMWR Surveill. Summ. 2008, 57:1-20.
33. Korn S.J., et al. Epileptiform burst activity induced by potassium in the hippocampus and its regulation by GABA-mediated inhibition. J. Neurophysiol. 1987, 57:325-340.
34. Kumar A. Long-term potentiation at CA3-CA1 hippocampal synapses with special emphasis on aging, disease, and stress. Front. Aging Neurosci. 2011, 3:7.
35. Kwan P., Brodie M.J. Early identification of refractory epilepsy. N. Engl. J. Med. 2000, 342:314-319.
36. Laeger T., et al. FGF21 is an endocrine signal of protein restriction. J. Clin. Invest. 2014, 124:3913-3922.
37. Lowenstein D.H. Status epilepticus: an overview of the clinical problem. Epilepsia 1999, 40(Suppl. 1):S3-S8. (discussion S21-2).
38. Mackenzie D.Y., Woolf L.I. Maple syrup urine disease; an inborn error of the metabolism of valine, leucine, and isoleucine associated with gross mental deficiency. Br. Med. J. 1959, 1:90-91.
39. Malenka R.C., Bear M.F. LTP and LTD: an embarrassment of riches. Neuron 2004, 44:5-21.
40. Masino S.A., Rho J.M. Mechanisms of Ketogenic Diet Action. Jasper's Basic Mechanisms of the Epilepsies 2012, National Center for Biotechnology Information (US), Bethesda. J.L. Noebels (Ed.).
41. Menkes J.H., et al. A new syndrome: progressive familial infantile cerebral dysfunction associated with an unusual urinary substance. Pediatrics 1954, 14:462-467.
42. Morrison R.S., et al. Loss of the p53 tumor suppressor gene protects neurons from kainate-induced cell death. J. Neurosci. 1996, 16:1337-1345.
43. Mutaguchi Y., et al. Identification, purification, and characterization of a novel amino acid racemase, isoleucine 2-epimerase, from Lactobacillus species. J. Bacteriol. 2013, 195:5207-5215.
44. Neal E.G., et al. The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial. Lancet Neurol. 2008, 7:500-506.
45. Ninomiya Y., et al. Analgesic effects of D-amino acids in four inbred strains of mice. Comp. Biochem. Physiol. C 1990, 97:341-343.
46. Noh H.S., et al. The protective effect of a ketogenic diet on kainic acid-induced hippocampal cell death in the male ICR mice. Epilepsy Res. 2003, 53:119-128.
47. Novarino G., et al. Mutations in BCKD-kinase lead to a potentially treatable form of autism with epilepsy. Science 2012, 338:394-397.
48. Orlova K.A., Crino P.B. The tuberous sclerosis complex. Ann. N. Y. Acad. Sci. 2010, 1184:87-105.
49. Payne E.M., et al. L-Leucine improves the anemia and developmental defects associated with Diamond-Blackfan anemia and del(5q) MDS by activating the mTOR pathway. Blood 2012, 120:2214-2224.
50. Potter W.B., et al. Metabolic regulation of neuronal plasticity by the energy sensor AMPK. PLoS One 2010, 5:e8996.
51. Pugliese A.M., Corradetti R. Effects of the antiepileptic drug felbamate on long-term potentiation in the CA1 region of rat hippocampal slices. Neurosci. Lett. 1996, 215:21-24.
52. Reaven G., Greenberg R.E. Experimental leucine-induced hypoglycemia in mice. Metabolism 1965, 14:625-631.
53. Samala R., et al. Anticonvulsant profile of a balanced ketogenic diet in acute mouse seizure models. Epilepsy Res. 2008, 81:119-127.
54. Sancak Y., et al. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 2008, 320:1496-1501.
55. Skeie B., et al. Effects of valine, leucine, isoleucine, and a balanced amino acid solution on the seizure threshold to picrotoxin in rats. Pharmacol. Biochem. Behav. 1994, 48:101-103.
56. Smith R.D., et al. Felbamate, a novel antiepileptic agent, does not affect cognition in rodents. Behav. Pharmacol. 1994, 5:365-368.
57. Stafstrom C.E., et al. Anticonvulsant and antiepileptic actions of 2-deoxy-D-glucose in epilepsy models. Ann. Neurol. 2009, 65:435-447.
58. Stawski P., et al. Pharmacology of ionotropic glutamate receptors: a structural perspective. Bioorg. Med. Chem. 2010, 18:7759-7772.
59. Steppuhn K.G., Turski L. Modulation of the seizure threshold for excitatory amino acids in mice by antiepileptic drugs and chemoconvulsants. J. Pharmacol. Exp. Ther. 1993, 265:1063-1070.
60. Traynelis S.F., Dingledine R. Potassium-induced spontaneous electrographic seizures in the rat hippocampal slice. J. Neurophysiol. 1988, 59:259-276.
61. Vertes R.P., Kocsis B. Brainstem-diencephalo-septohippocampal systems controlling the theta rhythm of the hippocampus. Neuroscience 1997, 81:893-926.
62. West P.J., et al. Antiseizure drugs differentially modulate theta-burst induced long-term potentiation in C57BL/6 mice. Epilepsia 2014, 55:214-223.
63. Yajima Y., et al. Effects of differential modulation of mu-, delta- and kappa-opioid systems on bicuculline-induced convulsions in the mouse. Brain Res. 2000, 862:120-126.
64. Yarmolinsky D.A., et al. Common sense about taste: from mammals to insects. Cell 2009, 139:234-244.
65. Yudkoff M., et al. Response of brain amino acid metabolism to ketosis. Neurochem. Int. 2005, 47:119-128.
66. Zeng L.H., et al. The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy. J. Neurosci. 2009, 29:6964-6972.